SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABSW
SAB Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.60+0.07 (+2.77%)
Close on Oct 19, 2026
- Market cap
- $207.36M
- P/E (TTM)
- –
- Dividend yield
- –
SAB Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $236.57M | $197.05M |
| Enterprise Value | $133.93M | $106.56M |
| PB Ratio | 1.10 | 2.14 |
| P/TBV Ratio | 1.10 | 2.46 |
Income (trailing twelve months)
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Operating Income | -$71.82M | -$21.44M |
| Net Income | -$12.78M | -$22.46M |
| EBITDA | -$68.85M | -$16.91M |
Returns
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -11.3% | -53.1% |
| Return on Assets (ROA) | -9.52% | -41.0% |
| Return on Invested Capital (ROIC) | -95.8% | -32.0% |
| Return on Capital Employed (ROCE) | -31.7% | -37.8% |
Balance sheet
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $102.63M | $62.42M |
| Net Cash (Debt) | $102.63M | $15.68M |
| Net Cash Per Share | $1.13 | $0.65 |
| Equity (Book Value) | $214.79M | $48.79M |
| Book Value Per Share | $2.36 | $1.36 |
| Tangible Book Value | $214.79M | $23.06M |
| Working Capital | $96.23M | $75.77M |
Financial position
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 9.22 | 3.30 |
| Quick Ratio | 8.77 | 2.39 |
| Interest Coverage | -310.26 | -7.12 |
Cash flow (trailing twelve months)
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$53.94M | -$12.35M |
Efficiency
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$148.55K | -$732.08K |
| Employee Count | 86 | 73 |
Dividends and yields
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -5.40% | -21.2% |
Shares
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 90,986,400 | 59,128,900 |
| Shares Change (QoQ) | 10.2% | 0.54% |
| Float | 63,497,000 | 48,744,500 |
| Shares Held by Insiders | 30.2% | 11.8% |
| Shares Held by Institutions | 76.1% | 59.4% |
Scores
| Measure | SAB Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 4.65 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from SAB Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.